EU Clinical Trial 2018-003794-98

A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)  Feb 20, 2019

Main objective of the trial: 1. To compare Progression-free Survival (PFS) as assessed by blinded independent central review according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, for the combinations of pembrolizumab (MK-3475) + lenvatinib (MK-7902) versus pembrolizumab + matching placebo 2. To compare Overall Survival (OS) for the combinations of pembrolizumab + lenvatinib versus pembrolizumab + matching placebo

Parties

Sponsors